ArticleAdvanced pharmaceutical bulletin2025
Well-regulated Dermal Regeneration Using Amnion-containing Scaffold in a Preclinical Study.
Article in Advanced pharmaceutical bulletin, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: we investigated the synergistic influence of amnion and keratinocytes on dermal regeneration in mice. Methods: A scaffold derived from amnion and gelatin via electrospinning was used to synthesize a polyurethane-based scaffold. polyurethane/gelatin/amnion (PU/G/A) scaffold was characterized by scanning electron microscopy (SEM), FTIR, and tensile test. biocompatibility of the corresponding scaffold was investigated using the MTT method in the culture of keratinocytes. Results: The SEM images showed sufficient cell adhesion on the PU/G/A scaffold. The tensile test results indicated that the scaffold containing PU/G/A with the lowest Young's modulus (12 MPa±2.1) displayed higher elasticity than the scaffold without amnion. Furthermore, the MTT assay revealed that the amniotic scaffold contributed to 100% cell viability ( Conclusion: This innovative nanofiber device not only addresses the limitations of traditional dressings but also offers additional functionalities such as wound compatibility, gas exchange, promotion of angiogenesis in the injured area and a substrate that amplifies the biological functions of stem cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.